Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

ABSTRACT:

Context

Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.

Objective

The objective of the study was to assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.

Design

This was an open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.

Setting

The study was conducted at 23 centers in Europe, the United States, and Canada.

Patients

The study included 17 patients with intractable PHPT and serum calcium greater than 12.5 mg/dl (3.1 mmol/liter).

Intervention

During the titration phase, cinacalcet d

SUBMITTER: Marcocci C 

PROVIDER: S-EPMC3214593 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature